Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report)’s stock price was down 0.1% during trading on Tuesday . The company traded as low as $392.54 and last traded at $397.01. Approximately 32,970 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 240,721 shares. The stock had previously closed at $397.25.
Analyst Ratings Changes
A number of equities research analysts recently commented on MEDP shares. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and boosted their target price for the company from $340.00 to $450.00 in a report on Tuesday, April 23rd. Finally, Guggenheim boosted their target price on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $443.00.
Medpace Stock Performance
The business’s 50-day moving average price is $396.31 and its 200 day moving average price is $343.28. The stock has a market capitalization of $12.29 billion, a PE ratio of 40.47, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The firm had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.27 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 11.29 earnings per share for the current year.
Insider Buying and Selling
In related news, CEO August J. Troendle sold 4,782 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the transaction, the chief executive officer now directly owns 716,197 shares in the company, valued at $286,894,194.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the sale, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO August J. Troendle sold 4,782 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total transaction of $1,915,573.56. Following the sale, the chief executive officer now owns 716,197 shares of the company’s stock, valued at $286,894,194.26. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 145,236 shares of company stock worth $59,626,117. Corporate insiders own 20.30% of the company’s stock.
Institutional Trading of Medpace
Institutional investors have recently added to or reduced their stakes in the business. RiverPark Advisors LLC purchased a new stake in Medpace during the fourth quarter valued at about $26,000. Contravisory Investment Management Inc. bought a new position in shares of Medpace during the fourth quarter valued at about $26,000. Rise Advisors LLC bought a new position in shares of Medpace during the first quarter valued at about $27,000. Mather Group LLC. bought a new position in shares of Medpace during the first quarter valued at about $28,000. Finally, GAMMA Investing LLC bought a new position in shares of Medpace during the fourth quarter valued at about $30,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.